Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Collection of Human Liver Biopsy and Whole Blood Samples From T1DM, TP or PP Patients for Potential Use for Insulin Producing Cells in Future Clinical Studies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04038931
Recruitment Status : Not yet recruiting
First Posted : July 31, 2019
Last Update Posted : September 24, 2019
Sponsor:
Information provided by (Responsible Party):
Orgenesis Ltd.

Brief Summary:

In this study, liver samples will be collected, processed and stored in a specialized, clinical grade, cell bank for potential future clinical use. A set of ex-vivo immunogenicity and transdiffrentiation tests will be carried to confirm the ability of this cryopreserved cell batch to be used as clinical grade raw material. Biopsies will be collected during TP or PP with the assumption that some of the patients (especially PP patients will not go through Islets autotransplantation) will develop brittle diabetes, thus Orgenesis therapy can provide them in the long run, a treatment. In terms of T1DM the purpose is to have available clinical grade raw material for cell replacement therapy.

The collected liver samples will be proliferated (up to passage 4) for future use. A portion of the stored cells will be utilized in a small-scale process to test possible immunogenicity performed on the collected blood sample. The assay will provide data whether immunomodulation treatment will be required in the future clinical trials. Also the transdffrentiated cells (AIPs) will be tested according to release criteria relevant for clinical IPC production. Liver biopsy donors will be contacted upon approval of the consecutive study and will have study recruitment priority. The donors can refuse to participate in the future study or may not need the therapy, however, their biopsies will be stored for a potential use if required, after the therapy is approved.


Condition or disease Intervention/treatment
Type 1 Diabetes Pancreatectomy; Hyperglycemia Other: Liver biopsy collection

Layout table for study information
Study Type : Observational
Estimated Enrollment : 20 participants
Official Title: Collection of Human Liver Biopsy and Whole Blood Samples From Type 1 Diabetes Mellitus (T1DM), Total or Partial Pancreatectomy Patients for Potential Use as an Autologous Source for Insulin Producing Cells in Future Clinical Studies
Estimated Study Start Date : October 1, 2019
Estimated Primary Completion Date : June 20, 2020
Estimated Study Completion Date : June 20, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Biopsy


Intervention Details:
  • Other: Liver biopsy collection
    Liver biopsy collection to Confirm suitability of T1DM, total or partial pancreatectomy patient's liver cells to be used as future personalized cell replacement therapy.


Primary Outcome Measures :
  1. Confirmation of patients' suitability eligibility to participate in future clinical study [ Time Frame: 1 year post biopsy collection ]
    Defined by a successful AIPs production from their liver biopsy.

  2. Evaluating autoimmune response to AIPs [ Time Frame: 1 year post biopsy collection ]
    Defined by Mixed Lymphocyte Reaction (MLR) assay based on the patient's PBMCs isolated from whole blood samples and following in-vivo subcutaneous implantation into the patients' arm



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
study population comprises of patients undergoing total or partial pancreatectomy or from T1DM patients undergoing an elective abdominal surgery (in which there is an easy access to the liver).
Criteria

Inclusion Criteria:

  • patients between the ages of 18 and 70 years old, inclusive.
  • For T1DM - Patients with history of established T1DM undergoing an elective abdominal surgery with an easy access to the liver
  • Patients undergoing total or partial Pancreatectomy
  • Female patients who agree not to breastfeed during the study up to at least seven days after the study is completed.
  • For T1DM - Receiving multiple daily insulin injections or insulin pump therapy.
  • For T1DM - HbA1c ≤10%.
  • Willing to sign the study informed consent document.
  • In good general health with no infections, or concomitant medical conditions that would influence the outcome of the trial, at the discretion of the Investigator and the Sponsor.

Exclusion Criteria:

  • Received any investigational product within 30 days of admission into this study or plan to participate in any other clinical study during the conduct of this study.
  • Received methotrexate or other rheumatoid disease modifying agents within the last 6 months.
  • Administration of a live vaccine 30 days prior to screening.
  • No evidence of liver Cirrhosis or Nonalcoholic Steatohepatitis (NASH, grade 3 and above) within the last month.
  • Patients diagnosed with liver viral infections such as HBV, HCV, HIV
  • Patients diagnosed with CMV (defined by IgM positive).
Layout table for additonal information
Responsible Party: Orgenesis Ltd.
ClinicalTrials.gov Identifier: NCT04038931    
Other Study ID Numbers: ORG-ISR-01
First Posted: July 31, 2019    Key Record Dates
Last Update Posted: September 24, 2019
Last Verified: September 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus, Type 1
Hyperglycemia
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases